Urothelial carcinoma is the most common type of bladder cancer and can develop in other parts of the urinary tract, including the renal pelvis, ureters, and urethra.

According to IARC global cancer estimates, more than 635,000 people were diagnosed with bladder cancer and over 225,000 died from the disease worldwide in 2024 alone.

At Bay Biosciences, we provide high-quality urothelial carcinoma samples for research, including human tumor biospecimens, fresh-frozen tissue, FFPE tissue, serum, plasma, peripheral blood mononuclear cells (PBMCs), and other biospecimens.

Understanding Urothelial Carcinoma

Urothelial carcinoma, also known as transitional cell carcinoma, is the most common type of bladder cancer. It develops in the urothelial cells that line the inside of the bladder and other parts of the urinary tract, including the renal pelvis, ureters, and urethra.

Most urothelial carcinomas begin in the bladder.

However, these tumors can also develop in the upper urinary tract. Depending on how deeply the tumor has invaded the bladder wall, urothelial carcinoma may be classified as non-muscle-invasive or muscle-invasive.

Urothelial carcinoma is biologically diverse.

Tumors may differ in their grade, stage, molecular characteristics, immune-cell composition, and response to treatment.

For this reason, researchers use well-characterized urothelial carcinoma samples for research to investigate disease mechanisms, identify biomarkers, and evaluate potential therapies.

Urothelial Carcinoma Patient Samples for Research

Symptoms of Urothelial Carcinoma

The most common symptom is blood in the urine, also known as hematuria. The urine may appear pink, red, or dark brown.

In some cases, blood is only detected through laboratory testing.

Other possible symptoms include:

Causes and Risk Factors of Urothelial Carcinoma

These are some common causes and risk factors of bladder cancer.

1. Occupational Chemical Exposure

Long-term exposure to certain industrial chemicals may increase the risk of urothelial carcinoma. Workers in industries involving dyes, rubber, leather, textiles, paints, and chemical manufacturing may have greater exposure to aromatic amines and other bladder carcinogens.

2. Increasing Age

The risk of urothelial carcinoma increases with age. Cancer-related genetic changes may accumulate over time, while the body’s ability to repair cellular damage may become less effective.

3. Previous Cancer Treatment

Certain chemotherapy drugs, including cyclophosphamide, have been associated with an increased risk of bladder cancer. Previous radiation therapy involving the pelvic region may also contribute to risk.

4. Chronic Bladder Irritation

Long-term bladder irritation or inflammation may increase the likelihood of developing bladder tumors. Possible contributors include recurrent infections, urinary stones, long-term catheter use, and certain parasitic infections in endemic regions.

5. Family History and Genetic Factors

A family history of bladder cancer may increase risk in some individuals. Certain inherited genetic changes may also affect the body’s ability to process carcinogens or repair damaged DNA.

6. Tobacco Smoking

Tobacco smoking is one of the strongest known risk factors for urothelial carcinoma. Chemicals in tobacco smoke enter the bloodstream and are filtered through the kidneys. These substances may collect in the urine and expose the bladder lining to carcinogenic compounds.

Diagnosis of Urothelial Carcinoma

Professionals usually begin the diagnosis of urothelial carcinoma with a medical history, physical examination, and urine testing.

They may also ask about urinary symptoms, smoking history, occupational exposures, previous cancer treatment, and family history.

Urine cytology may be conducted to examine urine for abnormal or malignant cells. Other urine-based tests may detect genetic changes, proteins, or molecular markers associated with bladder cancer.

Cystoscopy is also an important diagnostic procedure.

During cystoscopy, a physician uses a thin instrument with a camera to examine the inside of the bladder and urethra.

If an abnormal area is identified, a biopsy or transurethral resection of the bladder tumor may be performed.

Pathologists also examine collected tissue to confirm the diagnosis and determine the tumor’s grade and stage.

Furthermore, histopathological analysis may also show whether the tumor is non-muscle-invasive or muscle-invasive.

Moreover, healthcare professionals may use imaging techniques such as ultrasound, computed tomography, magnetic resonance imaging, or CT urography to evaluate the urinary tract and assess possible spread.

They may recommend additional scans when they suspect advanced disease.

Treatment of Urothelial Carcinoma

Treatment depends on the tumor’s stage, grade, location, molecular characteristics, overall health, and previous treatment history.

For non-muscle-invasive urothelial carcinoma, treatment may include transurethral resection of the bladder tumor.

Some patients may also receive intravesical therapy, in which medication is delivered directly into the bladder.

Bacillus Calmette–Guérin and intravesical chemotherapy are examples of treatments used in selected cases.

Muscle-invasive bladder cancer may require more intensive treatment.

Depending on the patient’s condition, options may include chemotherapy, radical cystectomy, radiation therapy, or combined treatment approaches.

Doctors may treat advanced or metastatic urothelial carcinoma with systemic chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, targeted therapies, or other treatments based on clinical and molecular findings.

Applications of Urothelial Carcinoma Samples for Research

Human Bladder Tumor Biospecimens

Human bladder tumor biospecimens may be used to study tumor structure, cellular composition, genetic alterations, and molecular pathways involved in bladder cancer development.

Urothelial Carcinoma Biospecimens for Research

Our Urothelial carcinoma biospecimens for research may include tumor tissue, blood-derived products, serum, plasma, PBMCs, tissue sections, and other clinically annotated specimens.

Urothelial Carcinoma PBMC Samples

PBMC samples contain peripheral blood mononuclear cells, including lymphocytes and monocytes. These immune cells can be used to investigate systemic immune responses associated with bladder cancer.

Researchers may study immune-cell populations, inflammatory signaling, immune activation, and responses to immunotherapy.

Similarly, PBMCs can be used alongside tumor tissue, serum, plasma, and clinical information to examine patient-to-patient biological differences.

Bladder Cancer Tumor Tissue for Research

Bladder cancer tumor tissue for research may support investigations into tumor morphology, cellular heterogeneity, gene expression, tumor-associated immune cells, and mechanisms of cancer progression.

Fresh frozen tissue may be useful for molecular studies that require preserved nucleic acids or other biological components. Tissue slides and FFPE blocks may support histological evaluation and biomarker validation.

Bladder Cancer Biomarkers Research

Bladder cancer biomarkers research focuses on identifying biological indicators that may help researchers understand disease development, tumor aggressiveness, recurrence, prognosis, or treatment response.

Potential research areas include:

  • Genetic mutations and genomic alterations
  • Gene-expression patterns
  • Protein and immune markers
  • Circulating tumor-related molecules
  • Urinary biomarkers
  • Tumor-infiltrating immune cells
  • Markers associated with treatment resistance
  • Biomarkers linked to immunotherapy response

Frequently Asked Questions

What are urothelial carcinoma samples for research used for?

Urothelial carcinoma samples for research are used to investigate tumor biology, disease progression, biomarkers, immune responses, treatment resistance, and potential therapies.

What types of human bladder tumor biospecimens may be used in research?

Human bladder tumor biospecimens may include fresh-frozen tumor tissue, FFPE tissue, biopsy specimens, and matched blood-derived products, depending on study requirements and availability.

Are research samples ethically sourced?

Yes. All biospecimens available on our website are sourced with ethical guidelines in mind.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide high-quality human biospecimens to support urothelial carcinoma research, biomarker discovery, translational studies, and drug development.

Our comprehensive range of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.